Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Paycom Software Inc (PAYC) vs 10X Genomics Inc (TXG) Price & Performance

Paycom Software IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Paycom Software Inc vs 10X Genomics Inc — how do they compare? Paycom Software Inc trades at $214.7 (market cap $9.88B), while 10X Genomics Inc trades at $67.62 (market cap $8.55B). The key difference: Paycom Software Inc is the larger of the two by market cap, and Paycom Software Inc pays a 0.68% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

PAYCTXG
Market Cap
$9.88B$8.55B
Sector
TechnologyHealth
52-Week High
$240.52$67.29
52-Week Low
$113.59$11.34
Enterprise Value
$10.66B$8.08B
Dividend Yield
0.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Paycom Software Inc

Paycom Software (PAYC) trades at $219.16, down 5.4% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal despite recent weakness, supported by positive analyst sentiment and institutional accumulation. Recent Q2 2026 results exceeded expectations with EPS of $2.78 beating estimates of $2.38, driving management's raised full-year guidance.

Outlook remains positive with a consensus price target of $231.70 offering 5.7% upside potential. Key opportunities include sustained revenue growth and expanding margins, while risks involve competitive pressures and market volatility. The company's strong cash flow generation and shareholder returns through dividends and buybacks support long-term value creation.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Paycom Software Inc

Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.

Read more on PAYC

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG